We report a case in which low-dose FP (5-fluorouracil/cisplatin, 5-FU/CDDP) therapy was remarkably effective for stage IVB advanced hepatocellular carcinoma (HCC) with lung and bone metastases. 5-FU of 250 mg/body/day was continuously infused over 24 hours and CDDP of 10 mg/body/day ...
After hepatic resection for HCC, the metastatic tumor progressed and became multiple lesions with mediastinal lymphnode involvements. Low-dose FP therapy was performed. Then, 250 mg/m(2)/day of 5-fluorouracil was given intravenously for 5 days weekly by continuous infusion and 10 mg/m(2)/day...
Toxicities of thalidomide were generally manageable, and only 16, 6, and 0 patients developed grade 2, 3, and 4 toxicities, respectively.Low-dose thalidomide is safe and induces unequivocal tumor response in a minority of patients with advanced HCC.Chiun...
Methods: Sixty- eight patients with unresectable and nonembolizable HCC were consecutively enrolled in a compassionate treatment program of oral thalidomide. Tumor response and treatment- related toxicity were prospectively followed. Thalidomide was given at a starting dose of 200 mg per day. The dose...
. Thinking in epidemiological terms often seems strange to clinicians who are used to think of the problem of each single patient.doi:10.1007/978-3-662-08422-9_5Professor Dr. Dr. h.c. Christian StrefferH. BoltD. FøllesdalP. HallE. SwatonSpringer Berlin Heidelberg...
Therefore it was very soon necessary to determine standards and dose limits for ionising radiation for persons at working places and later, also for individuals of the general population. The first standards were defined in the twenties and developed during the 20 th century based on that ...
However, the actual results show that ∆Hcc and ∆Hm of the blending system are not correlated with the mass ratio of the LPLA in the system, which reveals that the crystallization behavior of the LPLA also occurs in the system, and the LPLA and HPLA are completely compatible, so ...
nsreiagaftteshseusoedrimenTwde2Tiio2otnfhdftMihbtshterNreiipnRbhoeumry,teitdoseharnaeosrnrugeeretpnehnrmoeetnseisrenuanctctthuilsetrahairtethaceeoccdhtnTewat2rnaiiogtsihnfteisetcbhdsireniininhnpey,ottdthrhhereeoesngTiwze2tenhasedtnpeiiruesrtcccrilhtnierbaiuurtchamtoiceontewntpraiooiislnfrtleietbcd...